Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.56 |
| ▸ | EED | O75530 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441808 | 0.82 | EED (0.64) | CYP11B2CYP11B1EEDBACE1 | |
| SCHEMBL10534361 | 0.82 | EED (0.50) | EEDHTR2AHTR2CBACE1 | |
| SCHEMBL21326135 | 0.80 | EED (0.42) | EED | |
| SCHEMBL29586558 | 0.80 | EED (0.42) | EED | |
| SCHEMBL10534315 | 0.79 | CETP (0.48) | EEDHTR2AHTR2CBACE1 | |
| SCHEMBL6439662 | 0.77 | EED (0.64) | CYP11B2CYP11B1EEDBACE1 | |
| SCHEMBL10536027 | 0.76 | EED (0.50) | EEDBACE1 | |
| SCHEMBL29500368 | 0.75 | DRD1 (0.51) | CYP11B2CYP11B1EED | |
| SCHEMBL14993506 | 0.74 | CHRNB2 (0.42) | CYP11B2CYP11B1EEDBACE1CHRNB2 | |
| SCHEMBL17671440 | 0.74 | EED (0.39) | CYP11B2CYP11B1EEDBACE1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |